Medicines Authority Logo
  • SiteMap
  • Careers
Decrease Font Size Reset Font Size Increase Font Size
  • Home

  • Organisation

    • About Us
      • Mission and Objectives
      • Directorates and Units
      • Committees and Working Groups
      • Annual Reports
      • Heads of Medicines Agencies
      • Working at the Medicines Authority
      • Career Opportunities
      • Bank and Payment Details
    • Data and Information
      • Freedom of Information
      • Data Protection
      • Presentations and Publications
    • Links
      • Pharmacy Roster
      • eHealth
      • Government of Malta
      • Heads of Medicines Agency
      • Innovative Medicines Initiative
      • European Medicines Agency
    • Home
  • Legislation

    • Introduction
      • Better Regulation
    • Legislation Documentation
      • Medicines Act
      • EU Legislation
    • Home
  • Consultation

    • EU & Medicines Authority Consultations
      • EU & Medicines Authority Consultations
    • Home
  • News & Events

    • News
      • Press Releases
      • Circulars
      • Other News
      • Past News
    • Events
      • Latest Events
      • Past Events
    • Home
  • Online Services

    • Online Services
      • Eudrapharm
      • EU Common Submission Portal
      • Medicines Authority Notifications
      • Servizz.gov.mt
      • Online Applications (E-Forms)
    • Home
  • Contact and Connect

    • On Line Forms
      • Enquiries and Feedback
      • Complaints
      • Complaints related to Advertising of Medicinal Products
      • Report Product Defect
      • Report a Side Effect - Adverse Drug Reaction (ADR)
    • Connect and Share
      • Engage with us on Facebook
      • Follow us on LinkedIn
      • Follow us on Twitter
      • Connect with us on Google
      • Watch our videos on YouTube
    • Find Us
      • Contact Details
    • Home
  • Search for Malta Medicine
    Search »
    Search »
    Advanced Search »
  • Patient/Consumer
  • Industry
  • Healthcare Professional
  • Registration of Medicinal Products
  • Pharmaceutical Activities and Inspections
  • Scientific Advice
  • Recalls and Rapid Alerts
  • Changes to prescription status
  • Safety Recalls
  • BREXIT - Regulatory considerations
  • Advanced Scientific Initiatives
  • Advertising
  • Borderline Products
  • Linguistic Checks
  • Safety
  • Clinical Trials
  • Enforcement and Market Surveillance

Activities

  • Registration of Medicinal Products
  • Pharmaceutical Activities and Inspections
  • Scientific Advice
  • Recalls and Rapid Alerts
  • Changes to prescription status
  • Safety Recalls
  • BREXIT - Regulatory considerations
  • Advanced Scientific Initiatives
  • Advertising
  • Borderline Products
  • Linguistic Checks
  • Safety
  • Clinical Trials
  • Enforcement and Market Surveillance

Clinical Trials

  • Home
  • >
  • Activities
  • >
  • Clinical Trials
  • Introduction

  • Regulatory Framework

  • Application to conduct a Clinical Trial

  • The Voluntary Harmonisation Procedure

  • Access to Information on authorised Clinical Trials

  • Reporting adverse events in Clinical Trials

Introduction

Clinical trials are performed to find out how a medicine works, what side effects it causes and how it is metabolised by the body. Trials are conducted on new medicines and at times using medicines that are already on the market in Malta.

Clinical trials refer to any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of one or more Investigational Medicinal Products (IMP). They are also used to identify any adverse reactions to one or more IMPs, and/or to study absorption, distribution, metabolism and excretion of one or more IMPs with the object of ascertaining their safety and/or efficacy.

Regulatory Framework

The legal framework for Clinical Trials with medicinal products for human use is set out in the Clinical Trials Regulations (Subsidiary legislation 458.43) implementing the European Clinical Trials Directive 2001/20/EC In Malta, clinical trials must be notified to the Maltese Licensing Authority (through the Medicines Authority) by the person, individual or group that takes overall responsibility for the trial (the sponsor), but a doctor or a dentist (the investigator) must always participate in the conduct of the trial. The Medicines Authority evaluates both the quality of the investigation and the patient safety of clinical trials. Clinical trials must also be notified to the health ethics committee established under the Clinical Trials Regulations (Subsidiary legislation 458.43), which performs an overall assessment of the trial's ethical aspects. Before a clinical trial can be started, approvals must be obtained from both the health ethics committee and the Licensing Authority.

Application to conduct a clinical trial

The requirements necessary to conduct a clinical trial as well as notification of amendments to an already authorised clinical trial can be found in The Guidance notes on Good Clinical Practice -1/02/2018. The guideline provides information on how to apply for a trial, assessment timelines, fees, how to report adverse events and inspections on clinical trials.

The Clinical trial Application Form can be accessed here

The Voluntary Harmonisation Procedure

In April 2009 the Clinical Trials Facilitation Group (CTFG) launched the Voluntary Harmonisation Procedure (VHP). This procedure allows sponsors of EU multi-national clinical trials to obtain a harmonised assessment of their Clinical Trial Authorisation (CTA) application by all the National Competent Authorities (NCAs) involved. The sponsor receives a single, harmonised set of questions which have been consolidated following scientific discussion between the Lead Member State (LMS) and the other Member States concerned. A single set of core documents are provided electronically to the VHP coordinator and a simultaneous and coordinated assessment of the data is undertaken according to fixed timelines by the Member States concerned.

Further information on how to submit an application via VHP and the documentation required can be found in the Guidance document for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications

Access to Information on authorised Clinical Trial

For access to information on the authorised pharmaceutical clinical trials that are ongoing in Malta an EU Clinical Trial public register is available.

Reporting Adverse events in clinical trials

The legal obligations of the sponsors of clinical trials are specified in Directive 2001/20/EC and the Clinical Trials Regulations (Subsidiary legislation 458.43). Further guidance on the requirements of sponsors and investigators is outlined in the "Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use" issued by the European Commission

Additional guidance on Serious Unexpected Suspected Adverse Reactions (SUSARs) and how to report SUSARs to the Medicines Authority is available in The Medicines Authority's Guidance Notes for Pharmaceutical Companies on Pharmacovigilance Obligations for Medicinal Products for Human Use

Feedback

The Malta Medicines Authority thanks you for the time taken to visit our website. We kindly invite your anonymous feedback on your experience with this webpage. Feedback may be given through our online form.

Back to Top
  • Facebook
  • You Tube
  • Twitter
  • LinkedIn
  • Google Plus
  • Marker

Medicines Authority
Sir Temi Żammit Buildings,
Malta Life Sciences Park,
San Ġwann SĠN 3000
Malta

E-mail: info.medicinesauthority@gov.mt

Telephone: 356 2343 9000 (from 7:30 to 15:45)

Helpline: 356 2343 9111 (from 9:00 to 12:00)

Fax: 356 2343 9161

  • gov mt logo
  • hma logo
  • picis logo
  • MCCAA Logo
  • NCPE Logo
Malta Medicine Authority © Copyright 2019
  • Accessability
  • Disclaimer
  • Privacy Policy
  • Freedom of Information
  • Copyright
  • Contact and Connect